Multiple strategies targeting whole-cell endothelial cells (39), tumor blood vessel antigens (40), epidermal growth factor receptor (EGFR) (41), CD105 (42), platelet-derived growth factor receptor (PDGFR)-β (43) and vascular endothelial growth factor receptor (VEGFR) (44) have been tested in preclinical models of BC. This evidence concerns the gene EGFR and neoplasm.